Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System

被引:21
作者
Cotes, Robert O. [1 ]
de Nesnera, Alex [2 ]
Kelly, Michael [3 ]
Orsini, Karen [3 ]
Xie, Haiyi [2 ]
McHugo, Greg [2 ]
Bartels, Stephen [2 ,3 ]
Brunette, Mary F. [2 ,3 ]
机构
[1] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30303 USA
[2] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA
[3] Bur Behav Hlth, US Dept HHS, Hanover, NH USA
关键词
Cardiometabolic; Side effects; Antipsychotic medications; Quality improvement; Metabolic monitoring; 2ND-GENERATION ANTIPSYCHOTICS; METABOLIC RISK; VETERANS; CHILDREN; DRUG; PHARMACOTHERAPY; IMPLEMENTATION; PREVALENCE; PREDICTORS; BARRIERS;
D O I
10.1007/s10597-015-9833-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Antipsychotic medications can cause serious cardiometabolic side effects. No recent research has broadly evaluated monitoring and strategies to improve monitoring in U.S. public mental health systems. To address this knowledge gap, we evaluated education with audit and feedback to leaders to improve cardiometabolic monitoring in a state mental health system. We used Chi square statistics and logistic regressions to explore changes in monitoring recorded in randomly sampled records over 2 years. In 2009, assessment of patients on antipsychotics was 29.6 % for cholesterol, 40.4 % for glucose, 29.1 % for triglycerides, 54.3 % for weight, 33.6 % for blood pressure, and 5.7 % for abdominal girth. In 2010, four of ten mental health centers improved their rate of adult laboratory monitoring. Overall monitoring in the state did not increase. Education for prescribers with audit and feedback to leaders can improve monitoring in some settings, but more intensive and/or prolonged interventions may be required.
引用
收藏
页码:685 / 694
页数:10
相关论文
共 40 条
[1]   Increasing off-label use of antipsychotic medications in the United States, 1995-2008 [J].
Alexander, G. C. ;
Gallagher, S. A. ;
Mascola, A. ;
Moloney, R. M. ;
Stafford, R. S. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) :177-184
[3]  
American Diabetes Association, 2004, Obes Res, V12, P362
[4]   Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme [J].
Barnes, T. R. E. ;
Paton, C. ;
Hancock, E. ;
Cavanagh, M. -R. ;
Taylor, D. ;
Lelliott, P. .
ACTA PSYCHIATRICA SCANDINAVICA, 2008, 118 (01) :26-33
[5]  
Barrett E, 2004, OBES RES, V12, P362
[6]  
Brown J. D., 2012, EVIDENCE BASED PRACT, P1
[7]   Prediabetes Assessment and Follow-up in Older Veterans With Schizophrenia [J].
Copeland, Laurel A. ;
Parchman, Michael L. ;
Zeber, John E. ;
Lawrence, Valerie A. ;
Downs, John R. ;
Miller, Alexander L. .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (10) :887-896
[8]   Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents [J].
Correll, Christoph U. ;
Manu, Peter ;
Olshanskiy, Vladimir ;
Napolitano, Barbara ;
Kane, John M. ;
Malhotra, Anil K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (16) :1765-1773
[9]   Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents [J].
Correll, CU ;
Penzner, JB ;
Parikh, UH ;
Mughal, T ;
Javed, T ;
Carbon, M ;
Malhotra, AK .
CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2006, 15 (01) :177-+
[10]   Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics [J].
Dhamane, Amol D. ;
Martin, Bradley C. ;
Brixner, Diana I. ;
Hudson, Teresa J. ;
Said, Qayyim .
JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (05) :360-374